Mural Oncology (NASDAQ:MURA – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect Mural Oncology to post earnings of ($1.98) per share for the quarter.
Mural Oncology (NASDAQ:MURA – Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same period in the prior year, the business posted ($3.57) earnings per share. On average, analysts expect Mural Oncology to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Mural Oncology Price Performance
Shares of Mural Oncology stock opened at $4.07 on Tuesday. The stock has a market capitalization of $70.12 million, a P/E ratio of -0.45 and a beta of 3.66. The business has a 50 day simple moving average of $3.88 and a two-hundred day simple moving average of $3.60. Mural Oncology has a 12 month low of $2.87 and a 12 month high of $5.12.
Analyst Ratings Changes
View Our Latest Analysis on MURA
Mural Oncology Company Profile
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Read More
- Five stocks we like better than Mural Oncology
- How to start investing in penny stocks
- Can TikTok Stock Picks Really Make You Rich?
- 3 Stocks to Consider Buying in October
- The “Quality” Rotation: Back to Basics Investing
- The 3 Best Fintech Stocks to Buy Now
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.